WO2025224692 - METHOD OF TREATING CANCER USING A GENE EXPRESSION SIGNATURE
National phase entry is expected:
Publication Number
WO/2025/224692
Publication Date
30.10.2025
International Application No.
PCT/IB2025/054329
International Filing Date
25.04.2025
Title **
[English]
METHOD OF TREATING CANCER USING A GENE EXPRESSION SIGNATURE
[French]
MÉTHODE DE TRAITEMENT DU CANCER À L'AIDE D'UNE SIGNATURE D'EXPRESSION GÉNIQUE
Applicants **
IMMUNOCORE LIMITED
Inventors
KIRK, Peter
COLLINS, Laura
GREENSHIELDS-WATSON, Alexander
RANADE, Koustubh
Priority Data
63/638,764
25.04.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 4627 | |
| EPO | Filing, Examination, Granting | 74752 | |
| Japan | Filing, Examination, Granting | 4428 | |
| South Korea | Filing, Examination, Granting | 6313 | |
| USA | Filing, Examination, Granting | 20990 |
Total:
111,110
Contact Us
Abstract[English]
The present disclosure provides a method of treating a cancer in a subject, the method comprising administering to the subject an effective amount of an immunotherapeutic, wherein the subject has been determined to have a T cell signature (TCS) comprising: (a) a composite expression level A comprising the expression of three or more genes selected from Thymocyte Expressed, Positive Selection Associated 1 (TESPA1), Cluster of Differentiation 28 (CD28), G Protein-Coupled Receptor 183 (GPR183), and Zeta-Chain-Associated Protein Kinase 70 (ZAP70) as measured by log2tpm corresponding to a composite log2tpm value of greater than or equal to 3.2; or (b) a composite expression level B comprising (i) the expression of three or more genes selected from TESPA1, CD28, GPR183 and ZAP70 as measured by log2tpm corresponding to a composite log2tpm value of greater than or equal to 3.2, minus (ii) the expression of Interferon Alpha Inducible Protein 27 (IFI27) gene as measured by log2tpm, wherein the composite expression level B corresponds to a value of greater than or equal to -0.25.[French]
La présente divulgation propose une méthode de traitement d'un cancer chez un sujet, la méthode consistant à administrer au sujet une quantité efficace d'un immunothérapeutique, le sujet ayant été déterminé comme présentant une signature de lymphocyte T (TCS) comprenant : (a) un niveau d'expression composite A comprenant l'expression de trois gènes ou plus choisis parmi le thymocyte exprimé, la sélection positive associée 1 (TESPA1), la classe de différenciation 28 (CD28), le récepteur couplé à la protéine G 183 (GPR183) et la protéine kinase associée à la chaîne zêta 70 (ZAP70) telle que mesurée par log2tpm correspondant à une valeur log2tpm composite supérieure ou égale à 3,2 ; ou (b) un niveau d'expression composite B comprenant (i) l'expression de trois gènes ou plus choisis parmi TESPA1, CD28, GPR183 et ZAP70 telle que mesurée par log2tpm correspondant à une valeur log2tpm composite supérieure ou égale à 3,2, moins (ii) l'expression du gène de la protéine inductible par l'interféron alpha 27 (IFI27) telle que mesurée par log2tpm, le niveau d'expression composite B correspondant à une valeur supérieure ou égale à -0,25.